Brief: Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance On All Primary And Secondary Endpoints

Fresh Tracks Therapeutics

07/10/2021 12:40

Oct 7 (Reuters) - Brickell Biotech Inc  BBI.O :
    * BRICKELL BIOTECH ANNOUNCES POSITIVE TOPLINE RESULTS,
ACHIEVING
STATISTICAL SIGNIFICANCE ON ALL PRIMARY AND SECONDARY ENDPOINTS,
FROM BOTH U.S. PHASE 3 PIVOTAL CLINICAL STUDIES OF SOFPIRONIUM
BROMIDE GEL, 15% IN PRIMARY AXILLARY HYPERHIDROSIS PATIENTS
    * BRICKELL BIOTECH INC - SOFPIRONIUM BROMIDE GEL, 15% WAS
GENERALLY WELL-TOLERATED
    * BRICKELL BIOTECH INC - PLAN TO SUBMIT A NEW DRUG
APPLICATION
(NDA) TO FDA IN MID-2022
    * BRICKELL BIOTECH INC - NO TREATMENT-RELATED SERIOUS
ADVERSE
EVENTS (SAES) WERE REPORTED

Source text for Eikon:  ID:nGNX2J10hS 
Further company coverage:  BBI.O 

 ((Reuters.Briefs@thomsonreuters.com;))